77th WHO Western Pacific Regional Committee Meeting: Statements
77th Session of the WHO Regional Committee for the Western Pacific, Manila, Philippines, 19th to 22nd October 2026

10: Hypertension control

The International Pharmaceutical Federation (FIP), representing pharmacists, pharmacy educators and pharmaceutical scientists, welcomes WHO WPRO's focus on strengthening hypertension prevention, detection and control as part of the regional vision "Weaving health for all".

The FIP position is that pharmacists should be systematically integrated into national NCD strategies across prevention, risk factor screening, early detection, medicines optimisation and long-term care. This is reflected in the FIP 2025 Statement of Policy on the role of pharmacists in NCDs and reinforced by the 2026 FIP Montreal Declaration on NCDs.

The FIP has also developed practical implementation resources, including the Hypertension Pharmacy Toolkit, Supporting patients with uncontrolled hypertension: A toolkit for pharmacists, cardiovascular disease guidance and professional development resources through the FIP NCD Programme.

This contribution is particularly relevant in the Western Pacific Region, where hypertension affects more than a quarter of adults but only 22% of those diagnosed have their condition under control. Pharmacists can assist the WHO WPRO in its aim to achieve controlled blood pressure in 100 million more people by 2029, through routine blood pressure checks, reliable availability of medicines, frontline workforce development and digital health for follow up and adherence as critical actions.

The FIP calls on WHO WPRO and Member States to:

1. Integrate pharmacists into national hypertension and NCD strategies, with defined roles in screening, referral, medicines optimisation, adherence support and follow up.
2. Enable routine blood pressure screening and appropriate referral through community pharmacy and other pharmacy settings, particularly in underserved communities.
3. Strengthen access to antihypertensive medicines and pharmacist-led medicines optimisation as essential components of hypertension control.
4. Support scalable pharmacist-led models, including digital approaches for monitoring, follow up and collaboration across primary health care.

The FIP stands ready to work with WHO WPRO and Member States to identify, share and scale evidence-based pharmacy models for hypertension control.

Fédération Internationale Pharmaceutique

International Pharmaceutical Federation

Andries Bickerweg 5
2517 JP The Hague
The Netherlands
-
T +31 (0)70 302 19 70
fip@fip.org
-
www.fip.org

President
Mr Paul Sinclair
Australia

Chief Executive Officer
Dr Catherine Duggan
Netherlands

Vice Presidents
Prof. Nadia Al Mazrouei
United Arab Emirates
Prof. Claire Anderson
Great Britain
Dr Naoko Arakawa
United Kingdom
Prof. Erem Bilensoy
Türkiye
Mr Sherif Guorgui
Canada
Mr Luís Lourenço
Portugal
Prof. Donald Mager
United States of America
Ms Raquel Martínez
Spain
Mr Robert Moss
Netherlands
Prof. Giovanni Pauletti
United States of America
Prof. John Pieper
United States of America
Prof. Toyin Tofade
United States of America

President-elect
Mr Lars-Åke Söderlund
Sweden